Back
Corporate News
Gland Pharma launches Sugammadex injection after USFDA approval, targeting $1.6 billion market
29-Jul-2026, 01:03
Gland Pharma Limited has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, which is bioequivalent and therapeutically equivalent to Merck Sharp & Dohme LLC’s BRIDION® Injection, and has launched the product on Day 1 through its marketing partner; the product had US sales of approximately USD 1.6 billion for the twelve months ending April 2026, according to IQVIA.
Gland Pharma Limited has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, which is bioequivalent and therapeutically equivalent to Merck Sharp & Dohme LLC’s BRIDION® Injection, and has launched the product on Day 1 through its marketing partner; the product had US sales of approximately USD 1.6 billion for the twelve months ending April 2026, according to IQVIA.